Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer

Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin.

Eric P. Winer, MD, chief of the Division of Women's Cancers, director of the Breast Oncology Program, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin. Winer says that while studies are currnetly being done regarding bevacizumab's effecacy in breast cancer, those studies may not move forward due to this information.